Prof. MD. Cengiz Gemici

Education and Specialization

• 1983-1990 Marmara University Faculty of Medicine

• 1991-1994 SSK Okmeydanı Hospital, Radiation Oncology Specialization

• 1994-1995 Paris Hospitals College of Medicine Diploma (Diplome du Collége de Médecine des Hopitaux de Paris)

• 1995-1996 University of Paris XI, Paris-Sud Faculty of Medicine, 'Oncology' Advanced Specialization Diploma (Attestation de Formation Spécialisée Approfondie de Cancérologie)

• 1996-1997 University of Paris XI, Paris-Sud Faculty of Medicine, 'Medical Oncology' Specialization Diploma (Attestation de Formation Spécialisée Approfondie d’Oncologie Médicale)

• 1995-1997 University of Paris XI, Paris-Sud Faculty of Medicine, 'Clinical Oncology' Diploma (Diplome d’Université de Carcinologie Clinique)

• 2017 Appointed as Associate Professor

Experience

• 1994-1995 Paris Tenon Hospital, Radiation Oncology

• 1995-1997 Paris Tenon Hospital, Radiation Oncology and Medical Oncology Advanced Specialization

• 1997-2000 Kartal Training and Research Hospital, Radiation Oncology

• 2000-2017 Kartal Training and Research Hospital, Head of Radiation Oncology Training

Professional Memberships

• ASTRO (American Society of Therapeutic Radiology and Oncology)

• ASCO (American Society of Clinical Oncology)

• Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H.
  Radiat Oncol. 2018
• Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO. BMC Cancer. 2018
• Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience. Ozyurt H, Ozden AS, Ozgen Z, Gemici C, Yaprak G. Curr Oncol. 2017
• Radiation field size and dose determine oncologic outcome in esophageal cancer. Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. World J Surg Oncol. 2016
• Is there any role of intravenous iron for the treatment of anemia in cancer? Gemici C, Yetmen O, Yaprak G, Ozden S, Tepetam H, Ozyurt H, Mayadagli A. BMC Cancer. 2016
• Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M. Tumour Biol. 2016
• Whole-brain radiation therapy for brain metastases: detrimental or beneficial? Gemici C, Yaprak G. Radiat Oncol. 2015
• SRS With or Without Whole-Brain Radiation Therapy for Those With 1 to 4 Brain Metastases: In Regard to Sahgal et al. Gemici C, Yaprak G. Int J Radiat Oncol Biol Phys. 2015
• Neuroendocrine/squamous gastric collision tumor: A rare entity. Erkol B, Tilki M, Comunoğlu N, Öven Ustaalıoğlu BB, Aker F, Sürmelioğlu A, Telli F, Gemici C, Kılıçoğlu ZG, Yeşil A. Turk J Gastroenterol. 2014
• Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. World J Gastroenterol. 2015
• Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer: in regard to Muijs et al. Gemici C. Int J Radiat Oncol Biol Phys. 2014
• A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. Support Care Cancer. 2014
• Progression-free survival benefit or health-related quality-of-life advantage: which one to choose?
  Gemici C. J Clin Oncol. 2013
• Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer. Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, Kocak M. Radiother Oncol. 2013
• Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Sevinc A, Seker M, Bilici A, Ozdemir NY, Yildiz R, Ustaalioglu BO, Kalender ME, Dane F, Karaca H, Gemici C, Gumus M, Buyukberber S. Hepatogastroenterology. 2011
• Lhermitte's sign: Review with special emphasis in oncology practice. Gemici C. Crit Rev Oncol Hematol. 2010
• Tumor lysis syndrome in solid tumors. Gemici C. J Clin Oncol. 2009
• Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Caglayan B, Torun E, Turan D, Fidan A, Gemici C, Sarac G, Salepci B, Kiral N. Ann Surg Oncol. 2008
• How can we determine the role of radiotherapy in the treatment of localized aggressive non-Hodgkin's lymphoma? Gemici C, Salepci T. J Clin Oncol. 2007
• The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Gemici C. Cancer. 2007
• Tumour lysis syndrome in solid tumours. Gemici C. Clin Oncol (R Coll Radiol). 2006
• Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy. Dabak R, Uygur-Bayramicli O, Gemici C, Yavuzer D, Sargin M, Yildirim M. World J Gastroenterol. 2006
• Encapsulating peritonitis and familial Mediterranean fever. Dabak R, Uygur-Bayramiçli O, Aydin DK, Dolapçioglu C, Gemici C, Erginel T, Turan C, Karadayi N. World J Gastroenterol. 2005
• Erythropoietin to treat anaemia in patients with head and neck cancer. Gemici C. Lancet. 2004
• Is liver disease an octreotide side effect? Uygur-Bayramiçli O, Gemici C. J Clin Gastroenterol. 2003
• Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients. Belkacémi Y, Pène F, Touboul E, Rio B, Leblond V, Gorin NC, Laugier A, Gemici C, Housset M, Ozsahin M. Strahlenther Onkol. 1998